Advertisement
Advertisement
CMMB
Chemomab Therapeutics Ltd. - ADR
2.16
USDSponsored
-0.04
-1.82%
Sep 25, 15:54 UTC -4
Closed
After-Market
2.17
+0.01
+0.69%
CMMB Earnings Reports
Positive Surprise Ratio
CMMB beat 4 of 23 last estimates.
17%
Next Report
Date of Next Report
Nov 18, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.11
Implied change from Q2 26 (Revenue/ EPS)
--
/-54.17%
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Chemomab Therapeutics Ltd. - ADR earnings per share and revenue
On Aug 19, 2026, CMMB reported earnings of -0.24 USD per share (EPS) for Q2 26, missing the estimate of -0.15 USD, resulting in a -56.86% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +9.42% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an decrease of -54.17% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
FAQ
What were Chemomab Therapeutics Ltd. - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Chemomab Therapeutics Ltd. - ADR reported EPS of -$0.24, missing estimates by -56.86%, and revenue of $0.00, 0% as expectations.
How did the market react to Chemomab Therapeutics Ltd. - ADR's Q2 2026 earnings?
The stock price moved up 9.42%, changed from $1.91 before the earnings release to $2.09 the day after.
When is Chemomab Therapeutics Ltd. - ADR expected to report next?
The next earning report is scheduled for Nov 18, 2026.
What are the forecasts for Chemomab Therapeutics Ltd. - ADR's next earnings report?
Based on 3
analysts, Chemomab Therapeutics Ltd. - ADR is expected to report EPS of -$0.11 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.